World-leading Cancer Researcher Professor Paul Workman Joins The Innovation Debate 2012, The Royal Society, 20th November 2012

 World-leading Cancer Researcher Professor Paul Workman Joins The Innovation
              Debate 2012, The Royal Society, 20th November 2012

  PR Newswire

  CHERTSEY, England, November 19, 2012

CHERTSEY, England, November 19, 2012 /PRNewswire/ --

              To watch the debate live register FREE today at 

Professor Paul Workman , Deputy Chief Executive and head of cancer
therapeutics at The Institute of Cancer Research, London, will join the
distinguished panel of world-leading experts and chairman Professor Jim
Al-Khalili for The Innovation Debate 2012 , taking place on 20 ^th November at
4pm at the Royal Society in London and webcast live at .

Together they will debate "How do we innovate in a time of austerity?" and
"Are we doing enough to nurture innovators of the future?"

Presenting his views on the current state of innovation, Professor Workman -
who has also been a scientific founder of two successful biotechnology
companies - said:

"We are facing a serious challenge to the whole cancer drug discovery and
development 'ecosystem'.

"We are making real progress but nowhere near as much as we could be in
converting the incredible increase in our understanding of how cancer develops
- especially our knowledge of the genomes of cancer cells - into new targeted
therapies for cancer patients.

"There is also a major challenge to the pharmaceutical industry in switching
from the previous one-size-fits-all blockbuster model to the new future, which
will be all about personalised medicines targeted to multiple small patient
groups based on cancer genes.

"At The Innovation Debate, I will discuss the important changes needed to
address these challenges and to realise the full potential of cancer research
for our patients. 

"There needs to be more investment in drug discovery and development carried
out by non-profit groups so that early-stage drug projects deemed too risky
for industry to take on can be pushed through quickly to test their potential
in the lab and in patients. 

"There needs to be a total rethink in regulation and pricing so that
life-extending personalised drugs - and especially the drug combinations that
are essential to prevent drug resistance - can be made more readily available
to cancer patients. We also need to see much greater and earlier access for
cancer patients to experimental as well as approved drugs. 

"I think many of the problems in the ecosystem can be solved by a much closer
working together of academia, industry, government and regulators. Everyone
can benefit if we get this right."

Professor Workman - a world leader in the discovery and development of
molecularly targeted cancer drugs and a passionate advocate of personalised
cancer therapy - will join fellow panellists who include: Professor Andre Geim
- who in 2010 was awarded the Nobel Prize for his groundbreaking work on
graphene, a one-atom-thick material made of carbon; Tudor Brown , former
President of semiconductor giant ARM, headquartered in Cambridge ;  Professor
Mariana Mazzucato , Professor in Economics at the University of Sussex;
Professor Paul Boyle , President of Science Europe, which promotes the
collective interests of European research organisations, and DR  Beau Lotto ,
neuroscientist attached to University College, London's Institute of

In a tough economic climate, innovation needs to remain the lifeblood of
science, technology and the economy. There is an urgent need to focus on how
best to promote and nurture innovation - today and in the future.

That is why The Innovation Debate 2012 - organised and funded by Astellas
Pharma Europe Ltd . - is bringing together influential and respected figures
from the worlds of science, technology, medicine, education, government,
industry and the media to discuss how best to encourage and nurture scientific
innovation. The aim of The Innovation Debate is to air crucial issues, draw
positive conclusions and to move the agenda forward.

Everyone - professionals in science and technology, students and the general
public - will have the opportunity to engage with The Innovation Debate
through online media, taking discussions far beyond the walls of the Royal

Join the Innovation Debate 2012

The Innovation Debate will encourage wider participation from the public and
science community via the website . Everyone
will have the opportunity to share their views on the critical challenges
facing science and innovation raised by The Innovation Debate and to submit a
question to the panel of experts. To watch the live webcast of the Debate from
4pm on November 20 ^th 2012, register today at

Join the debate now at and follow us on
Twitter @Innovatedebate #innovationdebate

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is the European headquarters
of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceuticals. The organisation's focus
is to deliver outstanding R&D and marketing to continue growing in the world
pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21
affiliate offices located across Europe, the Middle East and Africa, an R&D
site and three manufacturing plants. The company employs approximately 4,300
staff across these regions. For more information about Astellas Pharma Europe,
please visit .

The Institute of Cancer Research, London, is one of the world's most
influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are
working every day to make a real impact on cancer patients' lives. Through its
unique partnership with The Royal Marsden Hospital and 'bench-to-bedside'
approach, the ICR is able to create and deliver results in a way that other
institutions cannot. Together the two organisations are rated in the top four
cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100
years. It provided the first convincing evidence that DNA damage is the basic
cause of cancer, laying the foundation for the now universally accepted idea
that cancer is a genetic disease. Today it leads the world at isolating
cancer-related genes and discovering new targeted drugs for personalised
cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher
education of international distinction. It has charitable status and relies on
support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer.

For more information visit

Contact: For further information, please contact: Mindy Dooa, Communications
Director, Astellas Pharma Europe Ltd, Tel: +44(0)203-379-8035, Mobile:
+44(0)7826-912-339, Email:
Press spacebar to pause and continue. Press esc to stop.